Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;13(2):125-134.
doi: 10.1007/s11899-018-0444-z.

Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities

Gunjan L Shah  1 , Navneet Majhail  2 , Nandita Khera  3 , Sergio Giralt  4
Affiliations
Review

Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities

Gunjan L Shah et al. Curr Hematol Malig Rep. 2018 Apr.

Abstract

Purpose of review: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture.

Recent findings: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.

Keywords: CAR-T cell; Cellular therapy; Hematopoietic cell transplantation; Value-base care.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Gunjan L. Shah, Nandita Khera, and Sergio Giralt declare no conflict of interest. Navneet Majhail is a consultant for Anthem, Inc.

Figures

Fig. 1
Fig. 1
Conceptual diagram of value-based care in hematopoietic cell transplantation
See this image and copyright information in PMC

References

    1. Majhail NS. Optimizing quality and efficiency of healthcare delivery in hematopoietic cell transplantation. Curr Hematol Malig Rep 2015;10:199–204. - PubMed
    1. Brown M, Brown G, Sharma S. Evidence-based to value-based medicine Chicago: AMA Press; 2005.
    1. Conrad DA. The theory of value-based payment incentives and their application to health care. Health Serv Res 2015;50:2057–89. - PMC - PubMed
    1. Porter ME. What is value in health care? NEJM 2010;363:2477–81. - PubMed
    1. Hashmi SK, Bredeson C, Duarte RF, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. BBMT 2017;23:717–25. - PMC - PubMed